Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech ...

Featured here, the Balance Sheet for Vivos Therapeutics Inc, which summarises the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...

Has Applied Therapeutics Inc. (APLT) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Applied Therapeutics Inc. is one of 1022 ...

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

This page features the latest news about the Unicycive Therapeutics stock. Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate ...

Just last week, Vivo unveiled the Vivo X200 series of flagship smartphones in its home market of China. These devices pack cutting edge technology and various AI powered features. But now, the ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $15.85.

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) and keeping the price target at $57.00. Terence Flynn’s rating is based on ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Toll-like receptors (TLRs) and their signalling pathways have therapeutic potential for the treatment of inflammation, cancer, infection, allergy and autoimmunity. The elucidation of the structure ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. ( LBE) announced that the 500 th lung transplant utilizing LBE’s ...